ESMO 2023 | TROPiCS-03: sacituzumab govitecan as a 2L treatment for ES-SCLC

In patients with extensive stage small cell lung cancer (ES-SCLC), treatment options are limited following progression from anti-PD-L1 therapy and chemotherapy. Andrea Ardizzoni, MD, PhD, University of Bologna, Bologna, Italy, discusses findings from the TROPiCS-03 study (NCT03964727) where sacituzumab govitecan showed promise as a second-line treatment for patients with ES-SCLC. Among 26 patients, the preliminary results revealed a 29% objective response rate and a 36% clinical benefit rate as well as a manageable safety profile suggesting the potential for sacituzumab govetican in this challenging setting.This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.